Table 2.
Weight loss of trackable individuals taking semaglutide
| Mean weight loss (kg) | Mean % weight loss | Lost >= 10% Weight | Lost >= 5% Weight | |
|---|---|---|---|---|
| Overall | ||||
| Males, N=1,600 | 4.35 (3.96, 4.72) | 3.66% (3.35, 3.97) | 12.75% (11.12, 14.38) | 36.44% (34.08, 38.80) |
| Females, N=1,955 | 5.09 (4.74, 5.45) | 5.08% (4.74, 5.41) | 22.46% (20.61, 24.30) | 46.39% (44.18, 48.60) |
| Overall, N=3,555 | 4.76 (4.50, 5.02) | 4.44% (4.21, 4.67) | 18.09% (16.82, 19.35) | 41.91% (40.29, 43.53) |
| 12 weeks from semaglutide exposure | ||||
| Males, N=416 | 2.88 (2.48, 3.29) | 2.46% (2.11, 2.80) | 2.56% (1.13, 4.00) | 21.79% (18.05, 25.54) |
| Females, N=603 | 3.65 (3.31, 3.99) | 3.57% (3.24, 3.91) | 6.90% (4.78, 9.01) | 34.48% (30.51, 38.45) |
| Overall, N=1,019 | 3.30 (3.03, 3.56) | 3.06% (2.82, 3.30) | 4.91% (3.58, 6.23) | 28.65% (25.88, 31.43) |
| 52 weeks from semaglutide exposure | ||||
| Diabetes, N=450 | 4.19 (3.49, 4.88) | 3.86% (3.26, 4.47) | 14.00% (10.79, 17.21) | 36.44% (32.00, 40.89) |
| Without Diabetes, N=89 | 7.94 (5.99, 9.88) | 7.44% (5.73, 9.15) | 33.71% (23.89, 43.53) | 58.43% (48.19%, 68.67%) |
| Males, N=225 | 4.39 (3.42, 5.36) | 3.76% (2.99, 4.52) | 13.33% (8.89, 17.78) | 33.33% (27.17, 39.49) |
| Females, N=314 | 5.10 (4.18, 6.03) | 4.95% (4.10, 5.80) | 20.06% (15.63, 24.49) | 44.90% (39.40, 50.41) |
| Overall,N=539 | 4.80 (4.13, 5.47) | 4.45% (3.87, 5.04) | 17.25% (14.06, 20.44) | 40.07% (35.94, 44.21) |
Metrics describing overall weight loss and proportion of individuals meeting significant weight loss thresholds for the overall cohort and cohorts observed at endpoints 12 weeks and 52 weeks after beginning taking semaglutide. The Diabetes group includes individuals diagnosed with Type 1 or Type 2 diabetes.
Note: Data is in the form Mean (0.25%, 97.5%). Data includes the average weight loss as a percent lost of initial weight, while the bottom two rows are the proportion of patients in the entire cohort that achieve ≥ 5% and ≥ 10% weight loss.